User:Mr. Ibrahem/Risdiplam

Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA). This includes type 1, type 2, and type 3 disease. It is used in those who are at least two months old. It is taken by mouth.

Common side effects included fever, diarrhea, rash, pneumonia, and vomiting. Use in pregnancy may harm the baby. It is a survival of motor neuron 2-directed RNA splicing modifier.

Risdiplam was approved for medical use in the United States in 2020 and Europe in 2021. In the United States 60 mg costs about 11,700 USD as of 2021. In the United Kingdom this amount costs the NHS about £7900.